Search Results - "Chiparus, Ovidiu"

Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial by Stein, Andrew, Wang, Wenping, Carter, Alison A, Chiparus, Ovidiu, Hollaender, Norbert, Kim, Hyewon, Motzer, Robert J, Sarr, Celine

“…The phase 3 RECORD-1 trial (NCT00410124) established the efficacy and safety of everolimus in patients with metastatic renal cell carcinoma (mRCC) who progress…”
Get full text

An image method to evaluate bagasse fiber dimensions by Chiparus, Ovidiu I., Chen, Yan

“…In the last 25 years the amount of textile nonwovens used for industrial and commercial applications increased more than 10 times. Bagasse fiber, a by-product…”
Get full text

Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants by Sechaud, Romain, Gu, Helen, Rahmanzadeh, Gholamreza, Chiparus, Ovidiu, Breitschaft, Astrid, Menssen, Hans D

“…PurposeMidostaurin, approved for FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis, is mainly metabolized by cytochrome P450 (CYP) 3A4…”
Get full text

Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants: Brief title: Drug-drug interaction of midostaurin by Sechaud, Romain, Gu, Helen, Rahmanzadeh, Gholamreza, Chiparus, Ovidiu, Breitschaft, Astrid, Menssen, Hans D.

“…Purpose Midostaurin, approved for FLT3 -mutated acute myeloid leukemia and advanced systemic mastocytosis, is mainly metabolized by cytochrome P450 (CYP) 3A4…”
Get full text

Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants by Sechaud, Romain, Gu, Helen, Rahmanzadeh, Gholamreza, Taylor, Amanda, Chiparus, Ovidiu, Sharma, Gopal Krishna, Breitschaft, Astrid, Menssen, Hans D.

“…Purpose Midostaurin, approved for treating FLT-3 -mutated acute myeloid leukemia and advanced systemic mastocytosis, is metabolized by cytochrome P450 (CYP)…”
Get full text

Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants by Sechaud, Romain, Gu, Helen, Rahmanzadeh, Gholamreza, Taylor, Amanda, Chiparus, Ovidiu, Sharma, Gopal Krishna, Breitschaft, Astrid, Menssen, Hans D.

Get full text

Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors by Goel, Varun, Hurh, Eunju, Stein, Andrew, Nedelman, Jerry, Zhou, Jocelyn, Chiparus, Ovidiu, Huang, Pai-Hsi, Gogov, Sven, Sellami, Dalila

“…Purpose Sonidegib (Odomzo) selectively inhibits smoothened and suppresses the growth of hedgehog pathway-dependent tumors. A population pharmacokinetic (PK)…”
Get full text

Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long‐Term Storage at Room Temperature by Tan, Eugene Y., Chiparus, Ovidiu, Choudhury, Somesh, Kim, Christina, Lau, Mike, Ziltener, Christoph, Ilankumaran, Palanichamy

“…Storage of trametinib tablets outside of 2‐8°C protected from moisture may lead to loss of dimethyl sulfoxide (DMSO) and adversely impact trametinib…”
Get full text

Dovitinib (TKI258): Exploration of pharmacokinetics and pharmacodynamics (PK/PD) for dose and regimen consideration by Garonzik, Samira Merali, Nedelman, Jerry, Tan, Eugene, Chiparus, Ovidiu, Dugan, Margaret Han

“…Abstract only 2603 Background: Dovitinib is a potent oral inhibitor of Receptor Tyrosine Kinases with activity against FGFR, VEGFR and PDGFR. The objectives of…”
Get full text

Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia by Yin, Ophelia Q. P., Giles, Frank J., Baccarani, Michele, le Coutre, Philipp, Chiparus, Ovidiu, Gallagher, Neil, Saglio, Giuseppe, Hughes, Timothy P., Hochhaus, Andreas, Kantarjian, Hagop M., Larson, Richard A.

“…Purpose The impact of proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2 blockers) on the efficacy of nilotinib was evaluated. Methods…”
Get full text

Kenaf/Ramie Composite for Automotive Headliner by Chen, Yan, Sun, Liangfeng, Chiparus, Ovidiu, Negulescu, Ioan, Yachmenev, Val, Warnock, Mary

“…An increasing industrial interest is applications of kenaf and ramie fiber nonwovens for making automotive interior trim parts because of their excellent…”
Get full text

Bagasse fibers for production of nonwoven materials by Chiparus, Ovidiu Iulius

“…Raw materials used in nonwoven products vary greatly, covering the entire spectrum from synthetic to natural fibers. The limitation of use for industrial…”
Get full text

Bagasse Fiber for Production of Nonwoven Materials by Chiparus, Ovidiu Iulius

“…Raw materials used in nonwoven products vary greatly, covering the entire spectrum from synthetic to natural fibers. The limitation of use for industrial…”
Get full text

Bagasse fibers for production of nonwoven materials by Chiparus, Ovidiu Iulius

“…Raw materials used in nonwoven products vary greatly, covering the entire spectrum from synthetic to natural fibers. The limitation of use for industrial…”
Get full text